Winslow Asset Management Inc. boosted its stake in Bio-Rad Laboratories, Inc. (NYSE:BIO – Free Report) by 2.7% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 21,443 shares of the medical research company’s stock after purchasing an additional 568 shares during the period. Bio-Rad Laboratories comprises approximately 1.8% […]
FDx Advisors Inc. acquired a new position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO – Free Report) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 598 shares of the medical research company’s stock, valued at approximately $214,000. A number of other hedge funds and […]
Advisor OS LLC grew its position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO – Free Report) by 6.0% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,020 shares of the medical research company’s stock after acquiring an additional […]
Bio-Rad Laboratories, Inc. (NYSE:BIO – Get Free Report) has been assigned a consensus recommendation of “Buy” from the four research firms that are covering the company, MarketBeat reports. Four investment analysts have rated the stock with a buy recommendation. The average 12 month price objective among brokerages that have updated their coverage on the stock […]
UBS Group started coverage on shares of Bio-Rad Laboratories (NYSE:BIO – Free Report) in a research report sent to investors on Thursday morning, MarketBeat reports. The brokerage issued a buy rating and a $395.00 price objective on the medical research company’s stock. Separately, StockNews.com cut shares of Bio-Rad Laboratories from a buy rating to a […]